Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 3/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15562504 | 0.83 | MAPT (0.34) | MAPTNPC1 | |
| SCHEMBL29571479 | 0.82 | NPC1 (0.36) | DGAT1NPC1 | |
| SCHEMBL3930727 | 0.82 | NPC1 (0.36) | DGAT1NPC1 | |
| SCHEMBL31460489 | 0.80 | DGAT1 (0.34) | DGAT1NPC1 | |
| SCHEMBL30855733 | 0.80 | DGAT1 (0.39) | DGAT1NPC1 | |
| SCHEMBL24344342 | 0.78 | DGAT1 (0.37) | DGAT1NPC1 | |
| SCHEMBL31276772 | 0.78 | DGAT1 (0.37) | DGAT1NPC1 | |
| SCHEMBL31219600 | 0.78 | DGAT1 (0.37) | DGAT1 | |
| SCHEMBL20129641 | 0.78 | DGAT1 (0.38) | DGAT1 | |
| SCHEMBL31219974 | 0.77 | DGAT1 (0.34) | DGAT1MAPTNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12577228-B2 | Dihydrocyclopenta-isoquinoline-sulfonamide derivatives compounds | UCB Biopharma SRL (BE) | 2026-03-17 | — | — | US | disclosed |
| US-20230303517-A1 | DIHYDROCYCLOPENTA-ISOQUINOLINE-SULFONAMIDE DERIVATIVES COMPOUNDS | UCB BIOPHARMA SRL (SOCIETE A RESPONSABILITE LIMITEE) (GB) | 2023-09-28 | — | — | US | disclosed |
| US-20230303517-A1 | DIHYDROCYCLOPENTA-ISOQUINOLINE-SULFONAMIDE DERIVATIVES COMPOUNDS | UCB BIOPHARMA SRL (SOCIETE A RESPONSABILITE LIMITEE) (GB) | 2023-09-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230303517-A1 | DIHYDROCYCLOPENTA-ISOQUINOLINE-SULFONAMIDE DERIVATIVES COMPOUNDS | FCER2, FCGR1A, FCGR2A | DGAT1 1769/4885MAPT 4462/4885NPC1 2106/4885 |
| US-12577228-B2 | Dihydrocyclopenta-isoquinoline-sulfonamide derivatives compounds | FCGR2A, FCER2, FCGR1A | DGAT1 1539/4885MAPT 4836/4885NPC1 567/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.